Introduction
Dr. Emili Montserrat is most well known for his work on prognostic factors and stem cell transplantation in CLL. In particular, he introduced ZAP-70 as a prognostic surrogate marker for Ig gene mutational status. He was also responsible for our understanding of the growth patterns seen in the bone marrow biopsy histology of CLL patients, he revived the clinical usefulness of the lymphocyte doubling time (LDT) originally described by Galton, and he wrote one of earliest editorials on the usefulness of minimal residual disease (MRD) in CLL.